Thermo Fisher Scientific expands its bioprocessing capabilities in Asia

Thermo Fisher Scientific company office in Silicon Valley, US [Credit: Michael Vi/Shutterstock.com].

Thermo Fisher Scientific has expanded its bioprocessing capabilities in India, Korea and Singapore as it seeks to boost its support for the Asian biopharma sector.

The new round of investment will add a new bioprocess design centre in Hyderabad, India and expand those already in use in Incheon, Korea and Singapore.

Daniella Cramp, Senior Vice President and President for BioProduction at Thermo Fisher Scientific, said: “Asia continues to play an increasingly important role in advancing innovation across the global biopharma industry.

“By expanding our network in Korea, Singapore and India, we’re bringing world-class infrastructure and expertise closer to our customers, helping them deliver high-quality biologics faster, more cost-effectively and more sustainably.”

The region is currently seeing increased demand for emerging modalities across biologics, vaccines and cell and gene therapies, with Thermo Fisher seeking to tap into this growth.

The three Asia bioprocess design centres will be connected as a ‘tri-hub’ network, which Thermo Fisher said would accelerates process development for its clients.

Across this network, the Incheon centre will focus on advanced materials, technologies and enhanced lab capabilities, with its Singapore counterpart offering access to bench-to-pilot scale bioprocessing, training and assistance with scaling early-stage processes.

Meanwhile, the new Hyderabad centre will be home to collaborative spaces for process design, simulation and optimisation.

Tony Acciarito, President, Asia Pacific and Middle East, Africa at Thermo Fisher Scientific, said: “Through advanced manufacturing, strategic partnerships and targeted regional investments, we are redefining what is possible in biologics production.

“We are proud to contribute to the transformation of Asia’s biopharma ecosystem and help our customers bring life-changing therapies to patients across Asia and beyond.”